Key Takeaways
- Sana Biotechnology’s average stock price target has decreased from $9.5 to $9.14, with estimates ranging from $7 to $16 per share.
- The updated target suggests a potential upside of approximately 230% based on the closing price on June 11.
- Analysts maintain a “Buy” consensus rating, consisting of 8 Buys and 1 Hold, with no Sell ratings.
Price Target Update for Sana Biotechnology
Recent estimates from a group of seven analysts indicate a decline in Sana Biotechnology, Inc.’s average stock price target from $9.5 to $9.14. The forecasts for the stock now range significantly, with estimates varying between $7 and $16 per share. At the closing price recorded on June 11, the updated target represents an enticing potential upside of about 230%.
The consensus rating for the stock remains solidly in the “Buy” territory, as reported by nine analysts covering the company. Notably, the recommendations include eight “Buy” ratings and one “Hold,” with no analysts issuing “Sell” ratings, emphasizing confidence in the company’s future prospects.
Investors can delve deeper into the price target data and comprehensive ratings for Sana Biotechnology, Inc. through the “Forecasts” tab, which also allows tracking of all past and future analyst recommendations.
Information regarding this stock comes with a disclaimer, with data sourced from FactSet. This content does not serve as personal investment advice and is strictly informational.
The content above is a summary. For more details, see the source article.